Lithium is an effective mood stabilizer for bipolar disorder patients and its therapeutic effect may involve inhibition of inositol monophosphatase activity. In humans, the enzyme is encoded by two genes, IMPA1 and IMPA2. IMPA2 maps to 18p11.2, a genomic interval for which evidence of linkage to bipolar disorder has been supported by several reports. We performed a genetic association study in Japanese cohorts (496 patients with bipolar disorder and 543 control subjects). Interestingly, we observed association of IMPA2 promoter single nucleotide polymorphisms (SNPs) (À461C and À207T) with bipolar disorder, the identical SNPs reported previously in a different population. In vitro promoter assay and genetic haplotype analysis showed that the combination of (À461C)-(À207T)-(À185A) drove enhanced transcription and the haplotypes containing (À461C)-(À207T)-(À185A) contributed to risk for bipolar disorder. Expression study on post-mortem brains revealed increased transcription from the IMPA2 allele that harbored (À461C)-(À207T)-(À185A) in the frontal cortex of bipolar disorder patients. The examination of allele-specific expressions in post-mortem brains did not support genomic imprinting of IMPA2, which was suggested nearby genomic locus. Contrasting to a prior report, therapeutic concentrations of lithium could not suppress the transcription of IMPA2 mRNA, and the mood-stabilizing effect of lithium is, if IMPA2 was one of the targets of lithium, deemed to be generated via inhibition of enzymatic reaction rather than transcriptional suppression. In conclusion, the present study suggests that a promoter haplotype of IMPA2 possibly contributes to risk for bipolar disorder by elevating IMPA2 levels in the brain, albeit the genetic effect varies among populations.
INTRODUCTION
Bipolar disorder is a major functional psychiatric illness along with schizophrenia, with a lifetime prevalence of B1%. It is characterized by recurrent episodes of mania and depression with chronic course (Evans et al, 2005) . Although pathological mechanisms for bipolar disorder remain largely elusive, the role of genetic factors in the etiology and the therapeutic efficacy of lithium have been established (Dinan, 2002; Gould et al, 2004) . Thus, genetic analysis of molecular components of pathways perturbed by lithium is a plausible strategy to gain insight into the pathophysiology of bipolar disorder.
The 'inositol-depletion hypothesis' has been proposed to explain the cellular action of lithium (Berridge et al, 1989; Gould et al, 2004; Gurvich and Klein, 2002; Harwood, 2005; Williams et al, 2002) . Recently identified neuroprotective effect of lithium may be mediated also through inositol depletion (Williams et al, 2002) . Several lines of evidence show that altered activity of inositol monophosphatase (IMPase) may be involved in the pathophysiology of bipolar disorder. IMPase (EC 3.1.3.25) catalyzes the release of the phosphate group from inositol monophosphate, an important step for the regeneration of free inositol. Reduced mRNA expression of IMPA2 in lymphocytes (Nemanov et al, 1999) or lymphoblastoid cells (Yoon et al, 2001) , and decreased concentration of inositol (Belmaker et al, 2002) or reduced IMPase activity (Shamir et al, 1998; Shaltiel et al, 2001 ) in lymphoblastoid cells from bipolar disorder patients have been reported.
We previously cloned the inositol(myo)-1(or 4)-monophosphatase 2 gene (IMPA2) (Yoshikawa et al, 1997 (Yoshikawa et al, , 2000 . IMPA2 has been targeted for genetic studies of bipolar disorder (Dimitrova et al, 2005; Sjholt et al, 2004; Yoshikawa et al, 2001) , because the gene is located on 18p11.2 (Yoshikawa et al, 1997) , a region that has been highlighted in several linkage studies (Berrettini et al, 1994; Detera-Wadleigh et al, 1999) and in a meta-analysis of genome scans for bipolar disorder (Segurado et al, 2003) . Sjholt et al (2004) detected association between IMPA2 promoter single nucleotide polymorphisms (SNPs) and bipolar disorder in 92 Palestinian Arab trios. IMPA2 is among tempting candidate genes in bipolar disorder based on convergent evidence from pharmacological, biochemical, linkage, and association analyses.
The major aims of present study are to (1) test whether previously reported association between promoter polymorphisms of IMPA2 and bipolar disorder can be replicated in large Japanese case-control cohorts, (2) examine which promoter haplotypes of IMPA2 are relevant to genetic predisposition and transcriptional regulation, and (3) assess whether the expression level of IMPA2 is altered in postmortem brains of bipolar disorder patients.
Here, we report support for previous findings on association between bipolar disorder and the promoter SNPs of IMPA2 in a different ethnic population, and that these SNPs exert effect on transcriptional activity both in vitro and IMPA2 transcript levels in bipolar disorder postmortem brains. These results warrant further inspection of the inositol hypothesis of bipolar disorder.
MATERIALS AND METHODS

Patients and Controls
A group of unrelated Japanese bipolar patients (242 men and 254 women) consisting of both bipolar I (162 men and 170 women) and bipolar II (80 men and 84 women), and age-and gender-matched controls (259 men and 284 women) were recruited through the COSMO (Collaborative Study of Mood Disorders) consortium in Japan (Kunugi et al, 2004; Munakata et al, 2004) . Each institute provided both case and control samples matched for gender, age, and geographic area. The mean (7SD) age of patients was 49.9714.6 years, and that of controls was 49.9711.7 years. Included in the analysis were 570 schizophrenics and the same number of age-and gender-matched controls . All subjects in this panel resided in central Japan. None of the schizophrenia patients had additional Axis-I disorders as defined by DSM-IV. Consensus diagnosis of bipolar disorder and schizophrenia was made according to criteria from DSM-IV by at least two experienced psychiatrists, on the basis of unstructured interviews, available medical records, and information from hospital staff and relatives. Control subjects were healthy volunteers who had neither current nor past contact with psychiatric services, and showed good social functioning. The control subjects were recruited from hospital staff, their associates, and company employees. They underwent psychiatric interviews at each institute, either in an unstructured manner or using a structured instrument (SCID). The present study was approved by the ethics committees of all participating institutes. All controls and patients gave informed written consent to participate in the study, after provision and explanation of study protocols and objectives.
SNP Genotyping of IMPA2
Genomic DNA was isolated from blood samples using standard methods. IMPA2 has a TATA-less and GC-rich promoter and the initiation codon is located in exon 1 (Yoshikawa et al, 2000) . SNPs that were analyzed were chosen from those detected in our prior genomic screening (Yoshikawa et al, 2001 ) and in the Sjholt et al (2004) report, and from databases, for example, NCBI (http:// www.ncbi.nlm.nih.gov/) and The International HapMap Project database (http://www.hapmap.org/index.html.ja) (Altshuler et al, 2005) . Genotyping was performed using the TaqMan system (Applied Biosystems, Foster City, CA), except for À461C4T, À241_237InsGGGCT, À207T4C, and À185A4G. Probes and primers were designed using Assays-by-Designt SNP genotyping (Applied Biosystems, Foster City, CA). PCR were carried out in an ABI 9700 thermocycler, and fluorescence was determined using an ABI 7900 sequence detector single point measurement and SDS v2.2 software (Applied Biosystems). The polymorphisms, À461C4T, À241_237InsGGGCT, À207T4C, and À185A4G were genotyped by direct sequencing using the BigDye Terminator Cycle Sequencing FS Ready Reaction kit (Applied Biosystems) and the ABI PRISM 3730 Genetic Analyzer (Applied Biosystems).
Statistical Analyses for Genetic Association
Deviations from Hardy-Weinberg equilibrium were computed using the Arlequin program (http://lgb.unige.ch/ arlequin/) (Schneider et al, 2000) . Allelic and genotypic frequencies of markers between patients and controls were assessed using Fisher's exact test. To determine the haplotype block structure in the region, we used the genotype data from all the samples (n ¼ 1039) and Haploview program (http://www.broad.mit.edu/mpg/haploview/) (Barrett et al, 2005) . Haplotype frequencies were computed using the expectation-maximization algorithm implemented in COCAPHASE ver2.35 (http://www.rfcgr.mrc.ac.uk/ fdudbrid/software/unphased/) (Dudbridge, 2003) . We used the program option, -zero 0.01. Haplotypes with a frequency below 1% were trimmed to zero, and assumed to be absent in the population when calculating degrees of freedom. Haplotype distributions were also evaluated using IMPA2 promoter and bipolar disorder T Ohnishi et al the COCAPHASE program. Empirical significance levels were simulated from 10 000 Monte Carlo permutations using the COCAPHASE program. For population homogeneity assessment of the bipolar and control samples, 20 genome-wide SNPs were selected randomly from the databases described above (Supplementary Table S1 ). The structure software (http://pritch.bsd. uchicago.edu/software.html) (Pritchard et al, 2000) was used to attempt to identify genetically similar diploid subpopulations by grouping individuals. In the application of this Markov chain Monte Carlo method, 1 000 000 replications were used for the burn-in period of the chain and for parameter estimation. The number of populations present in the sample (K) was unknown, so analysis was run at K ¼ 1, 2, 3, 4, and 5. From these results, best estimate of K was found by calculating posterior probabilities, Pr (K ¼ 1, 2, 3, 4, or 5), as described by Pritchard et al (2000) .
Plasmid Constructs for IMPA2 Promoter Assay
For IMPA2 promoter assay, we prepared constructs in pGL3-basic (Promega, Madison, WI) by amplifying genomic DNA with the following primers: FW, 5 0 -AGT GACGCGTGTGAAGAGTTTATAAAGTCCAGCC (3 0 end at nt À1185, A of the initiation codon ATG as + 1); and RV, 5 0 -AGTGAAGATCTTGCGCTGGCGGGAAGGGCA (3 0 end at nt À163). The amplicons from genomic DNA from subjects harboring appropriate haplotypes were directly cloned into the MluI/BglII site of pGL3-basic vector. The structure of each construct was verified by sequencing. pRL-TK (Promega) was used as an internal control reporter vector. The vector pGL3-control containing the SV40 promoter was used as a positive control.
Cell Culture, Transfection, and Luciferase Assay
The neuroblastoma cell line NB-1 was purchased from the Japanese Collection of Research Bioresources (Tokyo, Japan). HeLa TetOff cell line was from Clontech (Mountain View, CA). NB-1 was cultured in Eagle's minimum essential medium (Sigma, St Louis, MO) and RPMI1640 (Sigma) (1:1), supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA). HeLa TetOff was cultured in Dulbecco's modified Eagle's medium (Sigma), supplemented with 10% fetal bovine serum (Invitrogen). These cell lines were grown in 10 cm culture dishes and passaged at 60-70% confluence (1-3 Â 10 5 cells/well) onto a 24-well plate, 1 day before transfection. Transfections were performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. One microgram of plasmid DNA (reporter: internal reporter ¼ 9:1) and 2 ml of Lipofectamine 2000 were mixed in 100 ml of OPTI-MEM (Sigma). After a 20-min incubation, 500 ml of OPTI-MEM was added to individual wells and the Lipofectamine 2000/plasmid mixture was then added to each well containing cells. The plate was placed in a CO 2 incubator at 371C. Five hours after transfection, medium was replaced with fresh medium with or without the indicated concentration of lithium chloride. The transcriptional assay was performed 48 h after transfection using the PicaGene Dual SeaPansy kit (Toyo Ink, Tokyo, Japan). Transfected cells were washed with PBS and incubated in 100 ml of cell lysis buffer for 15 min at room temperature with shaking. Next, 100 ml of luciferase assay reagent was added to each cell lysate. The dual luciferase assay was carried out using a Lumat LB 9507 (EG&G Berthold, Bad Wildbad, Germany).
To examine the effect of lithium on the promoter activity of IMPA2, experiments were performed as follows: 5 h after transfection with one of test constructs in combination with an internal control vector, cells were treated with or without indicated concentration of lithium chloride in normal growth medium. The dual luciferase assay was performed 48 h after transfection as described above.
All luciferase assays were performed as three independent transfections, with each transfection performed in duplicate. We used the Fisher's PSLD test to evaluate transcriptional differences among multiple groups. Table S2 ). Diagnoses were made according to the DSM-IV. There were no significant demographic differences between the bipolar and control brains (Torrey et al, 2000) . This study was performed unblinded. Single-stranded cDNA was synthesized from 3 mg of total RNA samples by Reverscript II (Wako Pure Chemical Industries, Tokyo, Japan) and oligo(dT) primers (Roche Applied Science, Indianapolis, IN).
cDNA Preparation from Post-Mortem Brains
Real-Time Quantitative RT-PCR
mRNA levels were determined by real-time quantitative RT-PCR, using TaqMan universal PCR mastermix, transcript-specific minor groove binding (MGB) probes (Assays-on-Demand, Applied Biosystems) and an ABI 7900 sequence detection system, as described before (AokiSuzuki et al, 2005) . The MGB probe for IMPA1 was derived from exons 7 and 8, and that for IMPA2 from exons 3 and 4. We used three different internal control probes for the assessment of IMPA1 and IMPA2 expression in the brain: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-actin (ACTB), and phosphoglycerate kinase 1 (PGK1). The PCR assay were performed simultaneously with test and standard samples and no template controls in the same plate. A standard curve plotting the cycle of threshold values against input quantity (log scale) was constructed for both the control genes and the target molecules (IMPA1 and IMPA2) for each PCR assay. All real-time quantitative PCR data was captured using the SDS v2.2 (Applied Biosystems). The ratio of the relative concentration of the target molecule to each internal control gene was calculated. We used the Mann-Whitney U-test (two-tailed) to detect significant changes in the target gene expression levels.
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Detection of Allele-Specific Expression of IMPA2
To deduce the effects of promoter SNPs on in vivo mRNA expression of IMPA2, and also to evaluate the possibility of allele-specific expression, we selected the brain samples whose genotypes were heterozygous on À185A4G SNP site. This SNP had the most upstream location on the cDNA for which genotypes could be determined. The more upstream SNP À207T4C SNP could not be genotyped in cDNA samples because of inability to design suitable primers for amplifying cDNA. cDNA from the heterozygous brain samples were amplified using a forward primer, 5 0 -GGGGAGCGGAAAGCAGGACG (3 0 end at nt À187), a reverse primer, 5 0 -GCCTGGAAGCACTCCTCCCAG (3 0 end at nt + 65 from the A), and Pwo SuperYield DNA polymerase (Roche Applied Science). PCR conditions were as follows: initial denaturation at 981C for 5 min, then 35 cycles at 981C for 45 s and 681C for 1 min, and a final extension at 681C for 10 min. PCR products were cloned into pCRII TOPO vector (Invitrogen), and 80 clones on average from each brain sample were picked up and sequenced as described above. The expression ratio of À185A:À185G alleles was evaluated by the Mann-Whitney U-test (two-tailed). The exact haplotypes constructed by (À461C4T)-(À207T4C)-(À185A4G) in the '(À185)-heterozygous' brain samples were determined by PCR on genomic DNA using a forward primer, 5 0 -TCGAGGCTCA-GAGGAGTTGGAG (3 0 end at nt À636), and a reverse primer, 5 0 -TCCCGCAGCTCTGTGCCTAGT (3 0 end at nt À125), followed by subcloning of amplicons into pCRII TOPO vector (Invitrogen) and sequencing.
RESULTS
LD Block Structure of IMPA2
We evaluated a total of 26 polymorphisms for genotyping accuracy and heterozygosity, and selected 19 SNPs for subsequent systematic genetic analyses (SNP01 to SNP19 in Figure 1a and Supplementary Table S3 ). The minor allele frequencies of À241_237InsGGGCT were 1% in both bipolar IMPA2 promoter and bipolar disorder T Ohnishi et al (n ¼ 496) and control (n ¼ 543) groups and were not included in the analysis. Sjholt et al (2000) identified possible two tandemly organized inositol/choline responsive element (ICRE)-like sequences separated by 34 bp and approximately 1.5 kb upstream of the ATG codon of IMPA2: 5 0 -ATTTTACGTGG (sense direction) and 5 0 -ATTTCA TAAGC (antisense direction). However, no polymorphisms were detected in these potentially interesting sequences in 48 subjects.
Pairwise marker LD statistics were determined by using the Haploview program (Barrett et al, 2005) . LD blocks were generated based on 95% confidence bounds on D 0 , employing the Gabriel et al (2002) algorithm. Here, a parameter of LD, D 0 is D normalized against the maximum value of D possible, given allele frequencies PA (at locus A) and PB (at locus B), D ¼ PABÀ(PA Â PB) (PAB is the expected haplotype frequency). In the Japanese samples, four LD blocks were evident for IMPA2 genomic region (Figure 1b) .
Genetic Association Analysis between IMPA2 and Mental Disorders
Allelic and genotypic frequencies of 19 SNPs on IMPA2 in the bipolar and control groups are summarized in Table 1 . Allelic distributions of SNP04 (À461C4T) and SNP05 (À207T4C) differed significantly, albeit modest, between bipolar patients and controls, with the modest overrepresentation of À461C (odds ratio ¼ 1.199) and À207T (odds ratio ¼ 1.196) alleles in the disease group. Although P-values did not survive correction for multiple tests, these results are consistent with those by Sjholt et al (2004) , who reported significantly preferential transmission of only these two alleles from parents to affected offspring (Supplementary Table S3 ). SNP16 (558C4T) displayed marginally significant genotypic association with bipolar disorder. However, genotype distributions of this SNP and other SNPs in LD block 4 (Table1 and Figure 1b) showed departure from Hardy-Weinberg equilibrium, thereby necessitating caution in the interpretation of association.
Exploratory sliding haplotype analysis was performed by implementing two-and three-locus windows. Sequential haplotypes from SNP02 through SNP05 within LD block 1, displayed evidence of association with bipolar illness (Table 2) , rendering the interval from SNP02 and SNP05 a minimum essential region for further functional inspection (see next section). As the haplotypes in each window are not independent of each other, we performed 10 000 permutations using the data to compute empirical P-values for haplotypic associations, where all SNPs and all haplotypes in each window were taken into account. We obtained a significant empirical P ¼ 0.0493 for the two-locus window (sliding between SNP01 and SNP05), a significant P ¼ 0.0479 for the three-locus window (sliding between SNP01 and SNP05), and a significant P ¼ 0.0405 for the four-locus window (SNP02-SNP05).
One of the causes of spurious/unreplicated findings in population-based association studies is sample stratification owing to population admixture. To exclude this possibility, we genotyped 20 SNPs (Supplementary Table  S1 ) randomly located throughout the genome. No evidence for stratification was identified in our bipolar and control samples, with a Pr (K ¼ 1)40.99. We are currently pursuing this issue, by examining B1500 SNPs and have so far found no evidence of stratification in our Japanese samples (in preparation).
We have reported previously genetic association of three IMPA2 SNPs with schizophrenia (n ¼ 302) (Yoshikawa et al, 2001) , SNP06, SNP10, and SNP 16 (Supplementary Table  S3 ). In the present study, association was tested on an expanded sample set (570 schizophrenics and 570 age-/ gender-matched controls) devoid of population stratification . Modest nominal genotypic association of SNP10 (IVS1-15G4A) with schizophrenia (P ¼ 0.0376, Supplementary Table S4) was detected. In addition, association with febrile seizure with IMPA2 SNPs 11 and 15 has been reported (Nakayama et al, 2004) . These results leave the possibility of allelic heterogeneity in IMPA2 among variable diagnostic categories, although the functional significances of these SNPs are unknown.
IMPA2 Promoter Analysis and Haplotype Analysis
Results from our genetic analysis and a prior study (Sjholt et al, 2004) suggest that a bipolar risk-conferring haplotype(s) or SNP(s) may reside within LD block 1 that includes the promoter region. Therefore, we set out to evaluate the functional roles of promoter SNPs, by performing reporter gene assay using NB-1 and HeLa TetOff cells. We generated constructs covering the 1.1 kb 5 0 -upstream region of IMPA2, which contained SNP02-SNP05 sites that displayed haplotypic association in a sliding manner, plus SNP06 site (Figure 2a ). SNP06 site was included because it showed marginal association (P ¼ 0.05) in the study of Sjholt et al (2004) . The four haplotypes shown in Table 3 accounted for naturally occurring haplotypes composed of SNP02-03-04-05-06. Four different plasmid constructs reflecting existing haplotypes for in vitro transcription assay ( Figure 2a ) were prepared. In the neuroblastoma NB-1 cell line, the combination of C at SNP04 site and T at SNP05 site, alleles that were more frequent in bipolar samples, elicited a trend of elevated transcriptional activity compared to the reverse T
(SNP04)-C (SNP05) constructs (T-A-T-C-G/T-G-T-C-G vs G-G-C-T-G)
, suggesting that the haplotypes constructed by bipolar-associated alleles may result in enhanced promoter activity in the brain (Figure 2b ). In the two plasmid constructs carrying C (SNP04)-T (SNP05), the one with A at SNP06 site displayed significantly higher luciferase activity than the construct with the alternative allele G at SNP06. In HeLa TetOff cells, the construct of C-T-A (SNP04-05-06) also showed the highest transcriptional drive (Figure 2c ). These in vitro data suggested a functional impact of haplotypes with C (SNP04)-T (SNP05) and in particular C (SNP04)-T (SNP05)-A (SNP06). There were no promoter haplotypes spanning SNP02-SNP06 that were significantly associated with bipolar disorder (Table 3) , but the haplotypes containing C (SNP04)-T (SNP05) gave odds ratios slightly greater than 1, suggesting that this combination of alleles constitutes a putative 'basic' risk haplotype. Both alleles at SNP06 were on this putative 'basic' risk haplotype (Table 3) , with A giving higher odds ratio than G. 
Examination of Lithium Effect on IMPA2 Promoter Activity
Recently, Seelan et al (2004) reported that addition of therapeutic concentration of lithium chloride (1 mM) in HeLa cells produced downregulation of the promoter activity of IMPA2, and they speculated that this action might be evoked through several 'negative lithium regulatory region homologies' located in the promoter region of IMPA2 (Figure 2a) . A putative lithium responsive region was originally reported by Wang et al (2001) in the mouse Macs gene encoding the MARCKS (myristoylated alaninerich C kinase substrate) protein. Therefore, we examined whether the findings of Seelan et al (2004) could be replicated in our assay system using IMPA2 promoter constructs shown in Figure 2a , which represented naturally occurring haplotypes. As shown in Table 4 , no suppression of promoter activity was seen in the presence of a therapeutic concentration of lithium ions (1 mM), in any of the constructs tested. In control constructs carrying the SV40 promoter, 5 mM LiCl displayed an inhibitory effect (Po0.0001) in HeLa TetOff cells (a derivative of HeLa cells), and 10 mM LiCl suppressed transcription efficiency in both NB-1 and HeLa TetOff cells (Po0.01 and Po0.0001, respectively). In IMPA2 promoter constructs, 5 and 10 mM LiCl elicited a trend for decreased transcription in HeLa TetOff cells. When compared to 1 mM LiCl, 10 mM LiCl induced significant suppression of transcription in the two
IMPA2 promoter constructs (T-A-T-C-G and G-G-C-T-A) in
HeLa TetOff cells (Po0.05). We did not observe any effects with 1 mM LiCl or any 'IMPA2 promoter-specific' transcriptional suppression by higher concentrations of LiCl.
Expression Analysis of IMPA1 and IMPA2 in Post-mortem Brains
We quantified IMPA1 and IMPA2 mRNA expression levels in the frontal region BA46 (DLPFC) from bipolar and control post-mortem brains, using MGB reactions. For IMPA1, transcript levels were not significantly different between bipolars and controls (Supplementary Figure S1) . Although IMPA2 mRNA in bipolar brains was significantly upregulated compared to control brains with respect to all the three internal control probes (Supplementary Figure S1) , the expressional differences became nonsignificant when we strictly adjusted sample pH (Supplementary  Table S5 ). Next, to examine allelic expression differences of IMPA2, we chose brain samples whose genotypes were heterozygous at À185A4G (SNP06). Sixteen control brain samples and 18 bipolar samples met this criterion. IMPA2 transcripts that carried À185A were significantly more abundant than À185G, in the control group (Po0.0001) and combined group (Po0.0001) (Figure 3 ). In the bipolar group, the proportion of the À185A allele exceeded 50%, although this was not statistically significant. This indicates that IMPA2 mRNA displays biallelic expression, and therefore it is unlikely that the IMPA2 is an imprinted gene. Examination IMPA2 promoter and bipolar disorder T Ohnishi et al of exact haplotypes of genomic DNA from the 34 brain samples heterozygous at À185 position by subcloning showed that À185A, À207T, and À461C were on the same DNA strand (gray circles in Figure 3 ), except for one control sample whose haplotype could not be determined owing to unsuccessful subcloning/sequencing. In contrast, only four samples out of 33 had (À185G)-(À207T)-(À461C) (black circles in Figure 3 ), half of which showed higher transcription (450% in Figure 3 ). These results show that the bipolar-associated À461C and À207T alleles were related to increased expression of IMPA2 in the brain.
DISCUSSION
We investigated possible association between IMPA2 SNPs and bipolar disorder in Japanese cases and controls. Alleles from two promoter SNPs, À461C (SNP04) and À207T 
Control T-G-T-C-G G-G-C-T-G G-G-C-T-A T-A-T-C-G
Relative luciferase activity SNP02-03-04-05-06 IMPA2 promoter and bipolar disorder T Ohnishi et al (SNP05) in the LD block 1 of the gene show nominally significant correlation with the increased risk for the disease. Although the effect is modest, it is important that these results are concordant with the findings by Sjholt et al (2004) , which showed significant overtransmission of À461C and À207T to offspring with bipolar disorder in Palestinian Arab trios. The detection of the same alleles from the same two 5 0 -upstream SNPs in the two different ethnic groups suggest that altered transcription of IMPA2 plays a role in the pathogenesis of bipolar disorder. In vitro dual luciferase assay using NB-1 cells unraveled the transcription-enhancing effect of the combination of À461C (SNP04) and À207T (SNP05) alleles. In accordance with these results, transcription of IMPA2 mRNA from alleles carrying À461C and À207T is upregulated in the frontal cortex of post-mortem brains of bipolar patients. The failure to detect haplotypic association (SNP02-03-04-05-06, Table 3 ) in the present study may be due to the weak genetic effect of putative risk (or protective) haplotypes as represented by weak odds ratios in Japanese population and/or dampening of statistical significance by increased statistical degree of freedom in haplotype analysis compared to single SNP-based analysis. In either case, the present sample size may not be sufficient to provide robust statistical power. The promoter function assay using both NB-1 and HeLa cells exposes potential impact of À185A allele (P ¼ 0.05 in the association study of Sjholt et al, 2004) on transcriptional activation. However, there is no association between the SNP06 and bipolar disorder. Possibly, both alleles of À185A4G SNP are bifurcately linked to the putative 'basic' risk haplotype (À461C (SNP04) and À207T (SNP05)). The genetic and functional data presented here suggest that the IMPA2 promoter haplotype, À461C and À207T, contributes to elevated risk for bipolar disorder by eliciting increased expression, and À185A allele further augments the transcriptional activity of the risk-conferring (À461C)-(À207T) haplotype. Recently, Dimitrova et al (2005) examined eight SNPs including À461C4T of IMPA2 for association with bipolar disorder, using 121 Bulgarian trios, 116 UK trios, and a panel of 174 cases and 170 controls. None of the SNPs reached statistical significance in any of the sample sets, although trends of overtransmission of À461C in Bulgarian trios and overrepresentation of À461C in unrelated cases were observed. As demonstrated in our Japanese study, the genetic effect of IMPA2 is modest; most likely much larger sample numbers are needed to derive a definitive conclusion.
We searched for transcription factor binding motifs in the regions spanning SNP04, SNP05, and SNP06 using the TFSEARCH database (http://mbs.cbrc.jp/research/db/ TFSEARCHJ.html) (threshold set at 85.0 point) (Heinemeyer et al, 1998) , and found that À207C (SNP05) creates a potential Sp1-binding site. Lin et al (2005) assessed the effect of age at onset (AAO) on linkage to bipolar disorder and reported that 18p11.2 may harbor a risk gene(s) for later-onset form (AAO421 years) of the disease. Accordingly, we divided our bipolar samples with AAO4/p21 years and AAO4/p31. But none of these subgroups showed association with the gene, partly suggesting that the IMPA2 may not have a major effect on AAO-dependent bipolars in Japanese.
It should be noted that the expression of certain genes is affected by sample pH. Indeed, the difference of IMPA2 mRNA levels in bipolar patients and controls was not significant after strictly adjusting the sample pH. However, allele-specific expression should be less affected by such confounding factors; thus the effect of promoter haplotype of IMPA2 on its expression in brain is robust to sample pH. The expression and genetic data from the current study as well as prior data (Sjholt et al, 2004) suggest that IMPA2 exerts a greater role than IMPA1 in conferring risk to bipolar disorder. The true physiological substrate(s) and activating cofactor(s), if needed, for IMPA2, and distinctive roles of IMPA1 and IMPA2 in brain remain to be demonstrated. Quite recently, lack of lithium-like behavioral and molecular effects in IMPA2 gene-trapped mice was reported (Cryns et al, 2006) . Nonetheless, the upregulation of IMPA2 in bipolar brains may be relevant to 'inositol depletion' hypothesis of lithium action in bipolar disorder (Berridge et al, 1989) , since in our ongoing experiments, we found that IMPA2 showed IMPase activity, albeit weak compared to that of IMPA1 in a conventional assay condition, and the activity was inhibited by the presence of lithium chloride (Ohnishi et al, 2007) .
Our data also reveal that therapeutic concentrations of lithium could not suppress the transcription of IMPA2 mRNA and the transcription-inhibitory effect of higher concentration of lithium was not specific to IMPA2 promoter, in contrast to the conclusions of Seelan et al (2004) where the effects of lithium on control promoter constructs like SV40 was not presented. Our results further suggest that, the mood-stabilizing effect of lithium could be generated via inhibition of enzymatic reaction rather than transcriptional suppression. Therapeutic doses of lithium need to be administered for at least 2 weeks before clinical effects are seen. To examine this issue, it would be necessary to establish cell lines with stable expression of IMPA2.
Previously, Yoon et al (2001) reported that IMPA2 showed sex-dependent expressional differences in postmortem temporal cortex. However, we did not replicate the finding in the frontal cortex, nor detected any sexdependent genetic association between IMPA2 and bipolar disorder (data not shown).
Another important information obtained from the current allelic expression analysis of IMPA2 is that the gene is transcribed from both paternal and maternal chromosomes, indicating that IMPA2 is not under genomic imprinting control. Corradi et al (2005) reported that GNAL, a gene close to IMPA2, and possibly other genes in the region encompassing GNAL, is subject to genomic imprinting, as deduced from the detection of methylated and unmethylated DNA in GNAL region. In general, imprinting phenomenon involves a cluster of genes in a stretch of genome and imprinted multiple genes in the same locus are coordinately regulated by an imprinting control region (Delaval and Feil, 2004) . Our results raise the necessity for further scrutiny on whether genomic imprinting occurs in the GNAL/IMPA2 locus. It is of note that imprinting effect may be tissue-specific (within brain regions), and partial imprinting may also occur in human genes (Buckland, 2004) .
In summary, we detected an association between IMPA2 and bipolar disorder in Japanese cohorts with the same SNPs reported in Palestinian Arabs. Although the P-values for allelic association did not survive correction for multiple tests and thus its genetic effect is modest in the Japanese, the present evidence obtained from combined genetic analysis, promoter assay and postmortem brain expression and allelic expression analyses suggest that the (À1051G)-(À708G)-(À461C)-(À207T)-(À185A) haplotype contributes to risk for bipolar disorder by enhancing IMPA2 transcription. Future large-scale attempts for replication and detailed biochemical characterization of IMPA2 are warranted.
